Resources
Adviser selection
How to Choose a Fundraising Adviser for a Private-Markets Fund
The useful test is not who has the largest address book. It is which adviser can resolve your actual fundraising constraints, with evidence, clear responsibilities and aligned terms.
A private-markets fund manager should choose a fundraising adviser by testing the work they can do for the proposed fundraise, the people who will do it and the evidence behind their approach. A familiar name or an impressive investor list does not answer those questions.
The adviser’s task might involve challenging the proposition, identifying plausible investors, organising diligence or extending a capable team’s reach. Those are different needs. Until the need is clear, comparisons between firms are mostly comparisons between presentations.
The following is a decision framework, not a ranking of advisers or a claim that every manager needs one.
Begin with the constraint, then define the mandate
Write down what is preventing a credible investor from moving towards a decision.
Perhaps the investment case is sound but attribution is difficult to explain. Perhaps the team has relevant relationships but cannot sustain a fundraising process while investing and managing the portfolio. Perhaps it needs access to a different type of investor. An adviser who is well suited to one problem may be poorly suited to another.
Ask each candidate to describe the work required before making introductions. What would they investigate? Which assumptions might they reject? What would make them recommend waiting?
A proposal becomes more useful when it identifies decisions and deliverables: the evidence to assemble, the investor segments to test, responsibility for materials, ownership of investor communication and the way unresolved diligence questions will be handled. A promise to “open doors” leaves most of the assignment undefined.
This is consistent with the level of transparency an LP may expect. The ILPA Due Diligence Questionnaire, for example, asks whether placement agents will be used and how they will be involved. An agent is part of the process the investor is evaluating, not a substitute for the manager’s own evidence.
Request evidence that can survive a second question
A relevant engagement matters more than a long list of engagements. Ask what made the assignment comparable: strategy, manager maturity, investor type, geography and the nature of the fundraising problem. Similar fund sizes alone may conceal very different situations.
Then establish which people did the work. A firm’s experience and the proposed team’s experience are related but distinct. Who will lead positioning discussions, speak to investors, manage follow-up and remain accountable when progress is slow?
Where references are appropriate, obtain them with the relevant parties’ permission. Ask about judgement under pressure, responsiveness and the accuracy of feedback, as well as the eventual outcome. A completed raise cannot, by itself, establish how much of the result was caused by the adviser.
Access also needs examination. An investor’s name on a slide does not establish a current relationship, a relevant mandate or an appetite for your strategy. Ask how the proposed audience was selected, what remains unknown and how those uncertainties will be tested. Confidentiality may limit what can be disclosed before engagement; it need not prevent a coherent explanation of the method.
Make incentives and boundaries explicit
The headline fee is only one part of the commercial arrangement. Establish what triggers payment, which investors or transactions it covers, how expenses are approved, what happens on termination and whether any obligations survive the mandate.
Existing relationships need particular care. The parties should understand how pre-existing investors, unsolicited approaches and later commitments will be treated. Ambiguity is easiest to resolve before either side believes it has created value.
Ask about competing mandates and allocation of the team’s attention. Conflicts are not confined to direct competitors: several attractive assignments may seek time from the same decision-makers or require the same scarce senior resource.
For funds, consider the investor-facing implications too. ILPA Principles 3.0 recommends disclosure of the GP’s economic arrangement with placement agents in the due-diligence materials provided to prospective LPs. That is an industry governance recommendation, not a universal statement of law or a market fee benchmark. The engagement’s actual drafting and disclosure requirements need to be settled for its circumstances.
Separate permission, capability and fit
Regulatory status and commercial suitability are different tests. Establish the legal entity being appointed, the activities it proposes to undertake and the jurisdictions involved. In the UK, the FCA Financial Services Register is a primary source for checking recorded status; it does not establish that a firm is the right adviser for a particular raise. Cross-border activity needs its own assessment. The SEC’s broker-dealer registration guide, for instance, discusses placement activity in a US legal context, not a global one.
Finally, compare an external mandate with doing the work internally, narrowing the raise or delaying it. An adviser should have a specific job that the manager cannot perform as well with the resources reasonably available.
The strongest candidate need not make the largest promise. It should make the clearest account of what must happen, what it can contribute and what remains the manager’s responsibility.
Sources and scope
- ILPA Due Diligence Questionnaire 2.0, November 2021, section 2.3. Public institutional due-diligence framework; individual LP requirements differ.
- ILPA Principles 3.0, June 2019, placement-agent economics and disclosure. Industry recommendations, not legislation.
- FCA Financial Services Register guidance, updated 13 February 2026. UK regulatory-status reference, not an adviser quality assessment.
- SEC Guide to Broker-Dealer Registration, last reviewed 12 December 2016; checked 30 October 2026. Used only as an illustration of activity-based US regulatory scope, not a current or comprehensive statement of applicable requirements.
